Background The recently launched nucleotide polymerase inhibitor sofosbuvir represents a significant turn in the treatment paradigm of chronic hepatitis C. While effective, sofosbuvir is also associated with a considerable cost. Objective The objective of this study was to evaluate the cost effectiveness of sofosbuvir-containing regimens in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 5 (HCV-G5) mono-infection in South Africa (SA). Design We constructed a lifetime horizon decision-analytic Markov model of the natural history of HCV infection to evaluate the cost effectiveness of sofosbuvir-ledipasvir (SOF/LDV) monotherapy against sofosbuvir triple therapy (SOF-TT) (sofosbuvir ? pegylated interferon and ribavirin [peg-INF/RBV]) and the current standard of care (SOC) (peg-INF/RBV) for patients with chronic HCV-G5 in the South African context. The model was populated with data from published literature, expert opinion and South African private sector cost data. The price modelled for sofosbuvir was the predicted South African private sector price of 82,129.32 South African rand (R) (US$7000) for 12 weeks. The analysis was conducted from a third-party payer perspective. Outcome Measures The outcome measures were discounted and undiscounted costs (in 2015 South African rand and US dollars) and quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs). Results Outcomes from the cost-effectiveness model show that SOF/LDV yields the most favourable future health economic outcomes compared with SOF-TT and the current SOC in SA. Findings relating to the lifetime incremental cost per QALY gained for patients infected with HCV-G5 indicate that SOF/LDV dominated both SOF-TT and SOC, i.e. SOF/LDV is less costly and more effective. Conclusion Outcomes from this analysis suggest that at a price of R123,190 ($US10,500) for 12 weeks of SOF/LDV might be cost effective for South African patients infected with HCV-G5.
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Introduction
Approximately 150 million people worldwide have chronic hepatitis C (CHC) virus (HCV) infection [1] . The burden of HCV in South Africa (SA) is poorly defined; however, it is estimated to be low (0.1-1.7 %). The seroprevalence in blood donors ranges between 1.4 and 1.8 % and in healthcare workers and HIV-positive patients ranges between 13 and 33 % [2] [3] [4] [5] [6] . In Africa, HCV genotypes 1 (HCV-G1), 4 and 5 (HCV-G5) dominate but regional variations occur [2, 3] . HCV-G5 is prominent in SA, accounting for 36 % of all confirmed HCV cases, followed by genotypes 1b (22 %), 3a (11.7 %) and 4 (8.91 %). Genotype 2 accounts for less than 2 % of HCV infections in SA [4] . Cirrhosis and hepatocellular carcinoma (HCC) complicates chronic infection and accounts for the rising incidence of HCC and chronic liver disease in several developed countries [7, 8] .
The existing standard of care (SOC) for all HCV genotypes in SA is the combination of pegylated interferon and ribavirin. Treatment duration for HCV-G5 infection is 48 weeks [9] . Treatment response is assessed sustained virologic response (SVR), defined as the absence of detectable HCV RNA by sensitive polymerase chain reaction (PCR) 24 weeks after the completion of therapy [10] . Treatment is expensive [around 195 ,000 South African rand (R) (*US$16,620) 1 for 48 weeks] and requires specialist care [12] . Overall, pegylated interferon and ribavirin (peg-INF/RBV) achieves SVR in approximately 50-55 % of patients, although differences do exist for different genotypes [13, 14] . Regimens that include the nucleotide polymerase inhibitor sofosbuvir significantly increases treatment success, shortens treatment duration and causes fewer adverse events than SOC in patients with chronic HCV infection [15, 16] . Overall SVR rates of 92 % for noncirrhotic and 80 % for cirrhotic patients, 12 weeks after therapy has ended, have been reported for patients with genotypes 1, 4, 5 and 6 treated with a combination of sofosbuvir and peg-INF/RBV [16] [17] [18] . Less than a year after the approval of sofosbuvir, an all-oral, fixed-dose combination of SOF and ledipasvir was approved by the US FDA for HCV-G1 [19] . For patients ineligible, intolerant or unwilling to take interferonbased regimens, the sofosbuvir-ledipasvir (SOF/LDV) combination represents a significant advance. To date, there have been no large randomised controlled trials (RCTs) that include efficacy data for SOF/LDV in HCV-G5; however, a small open-label study conducted in France found that SOF/LDV administered as monotherapy for 12 weeks in treatment-naïve and treatment-experienced patients infected with HCV-G5 yielded an SVR rate of 95 %, irrespective of cirrhosis status [20] . Based on these results, both the European Association for the Study of the Liver (EASL) [21] and American Association for the Study of Liver Diseases (AASLD) [22] amended their guidelines to include sofosbuvir ? peg-INF/RBV and SOF/ LDV for HCV-G5 infection. While highly effective, these new drugs are very costly: in the US sofosbuvir (Sovaldi Ò ) is priced at US$84,000 (*R985,552) and SOF/LDV (Harvoni Ò ) is priced at US$94,500 (*R1,108,746) for a treatment course for 12 weeks, eliciting a global debate on the pricing of new HCV drugs [23] . Sofosbuvir is not yet registered in SA and its pricing has not yet been established. Our study was premised on the need to integrate evidence of clinical and economic outcomes in order to determine if sofosbuvir-containing regimens will be cost effective for the treatment of chronic HCV-G5 in SA.
Methods
We constructed a decision-analytic Markov model of the natural history of HCV infection and progression toward advanced liver disease so as to evaluate the cost effectiveness of sofosbuvir-containing regimens versus the current SOC for treatment-naive patients with chronic HCV-G5 in the South African context. The natural history model simulates the journey of a hypothetical cohort of patients with chronic HCV-G5 infection through defined health states over a lifetime period until death. Given the slow progression of chronic HCV infection and that treatment benefits are expected in the long term, a lifetime horizon model with an annual cycle length was constructed. In keeping with the South African pharmacoeconomic guidelines [24] , a thirdparty payer (i.e. funder) perspective was adopted and future costs and benefits were discounted at a baseline annual discount rate of 5 % [24] .
Model Overview and Assumptions
The model consisted of an initial decision tree, in which patients were eligible to receive treatment and a statetransition Markov model to simulate the natural history of CHC and project patients' outcomes. The model structure is described in more detail in Online Resource A (Electronic Supplementary Material). Figure 1 shows the health state transitions included in the model following the decision tree. In brief, a cohort of patients with chronic HCV-G5 infection is entered into the model and followed as they age. The modelled cohort moves between defined health states on an annual basis according to annual transition probabilities, based on best available evidence (Table 1) . Health states included in the model were CHC without cirrhosis, compensated cirrhosis, decompensated cirrhosis, HCC, SVR without cirrhosis, SVR with cirrhosis, liverrelated death and non-liver-related death.
In our model, compensated cirrhosis is defined as METAVIR fibrosis score F4 and chronic HCV without cirrhosis is defined as METAVIR fibrosis scores 2 F2-3.
Fibrosis BF1 was excluded from our model as the existing HCV management guidelines prioritises treatment for patients with CF2 fibrosis due to resource constraints [9] . Decompensated cirrhosis included those with ascites, oesophageal varices and hepatic encephalopathy. At the initiation of the model, patients started in one of two disease states: CHC without cirrhosis or compensated cirrhosis. Patients could follow one of three different paths in each 1-year cycle: (a) continue in the same health state without suffering from any event; (b) die of non-liver-related causes; or (c) progress to the next health state in the natural history model, based on their transition probabilities, irrespective of the treatment option chosen. Death from any cause not related to HCV could occur from any state and was estimated by applying age-and sex-specific rates of mortality, calculated as a multiple of the mortality in the general population of the same sex for a specific age (Online Resource A). Liver-related death was only possible from decompensated cirrhosis and HCC states. The model allowed for antiviral treatment to be applied at two progressive states of the disease: CHC without cirrhosis and compensated cirrhosis. Patients initiated treatment as they entered the model and patients could only enter the model at the beginning. Treatment strategies for HCV-G5 infection included (1) SOC (peg-INF/RBV); (2) sofosbuvir triple therapy (SOF-TT) (sofosbuvir ? peg-INF/RBV); and (3) SOF/LDV (fixed-dose, once-a-day tablet). To be consistent with current guidelines, we assumed a 48-week treatment duration for SOC and 12-week treatment durations for both sofosbuvir-containing regimens [9, 21, 22] .
Patients were assumed to complete only one course of treatment before achieving SVR. Patients who achieved SVR were assumed to maintain SVR and experience no further disease progression until their death. Every patient Table 1 . CHC chronic hepatitis C, HCC hepatocellular carcinoma, SVR sustained virologic response 2 The METAVIR scoring system is a scoring method used for measuring the degree of liver inflammation and staging of fibrosis in patients with hepatitis C. It uses a grading and a staging system where the grade indicates the amount of inflammation and the stage represents the amount of fibrosis or scarring. The grade is usually scored from 0 to 4 (0 = no activity and 3 or 4 = severe activity). The fibrosis score is also assigned a number from 0 to 4 (0 = no scarring; 1 = minimal scarring; 2 = scarring extending outside the areas in the liver that contains blood vessels; 3 = bridging fibrosis, spreading and connecting to other areas that contain fibrosis; and 4 = cirrhosis or advanced scarring of the liver) [41] . CHC chronic hepatitis C, HCC hepatocellular carcinoma, HCV hepatitis C virus, peg-INF pegylated-interferon, RBV ribavirin, SOC standard of care, SOF sofosbuvir, SOF/LDV sofosbuvir-ledipasvir, SVR sustained virologic response a The annual probability of CHC to cirrhosis was calculated from assumed probability of 20 % over 20 years (see Online Resource A). Sensitivity analyses were performed to account for lower and higher (10 vs. 30 % over 10 years) rates of progression who survived each 1-year cycle received 1 life-year gained (LYG 
Patient Population
We considered a cohort of hypothetical treatment-naive HIV-negative patients with HCV-G5 infection. Baseline characteristics for the study population were based on the patient demographics of a South African HCV cohort [25] . The cohort was characterised by age, sex and according to the presence/absence of cirrhosis. The cohort was not stratified according to ethnicity or interleukin (IL)-28B genotype, as ethnicity and IL-28B polymorphisms are seemingly not predictive of the SVR rate in South African patients infected with HCV-G5 [25, 42] .
Data and Sources

Clinical Data
Clinical inputs, including annual transition probabilities, treatment efficacy and treatment duration, are shown in Table 1 . The annual transition probabilities for progressing from one disease state to the next were derived from the literature. Based on estimates of transition probabilities from CHC to cirrhosis [26] , we assumed a transition probability of 20 % over 20 years, converted to an annual probability (see Online Resource A for calculations). Probabilities for HCV-related death were taken from the literature, whereas sex-and age-specific mortality rates from causes other than HCV were taken from the 2008 version of the Actuarial Society of South Africa (ASSA) HIV demographic model [31] . Dosing and administration of SOF-TT and SOF/LDV were based on the treatment regimens as per the EASL and AASLD recommendations. Patients in the SOF-TT arm received 400 mg oral sofosbuvir daily together with oral, weight-based ribavirin and 180 lg of pegylated interferona-2a subcutaneously weekly for 12 weeks, irrespective of cirrhosis status [21, 22] . Non-cirrhotic patients in the SOF/ LDV arm received a combination of sofosbuvir 400 mg and ledipasvir 90 mg in a single tablet once daily for 12 weeks. In the base-case analysis, cirrhotic patients received the same fixed-dose combination for 12 weeks with weight-based ribavirin daily [21, 22] . The primary efficacy measure used in the model was SVR, 12 and 24 weeks after completion of treatment for sofosbuvirbased therapy and SOC, respectively. SVR rates for patients who initiated treatment while in the 'compensated cirrhosis' state were considered to be lower than for patients who initiated treatment while in the 'CHC without cirrhosis' state. Response rates for SOF-TT were based on the results of the NEUTRINO trial [16] . A limitation is that the NEUTRINO trial only included one HCV-G5 patient; however, to date, most trials have unfortunately included very limited numbers of HCV-G5 patients, and at the time of this analysis, the NEUTRINO trial was the only major registration trial containing HCV-G5 patients. Response rates for SOF/LDV were based on the results of the openlabel study conducted by Abergel et al. [20] in France. Treatment efficacy of SOC was based on pooled results from the BERNAR-1 and BERNAR-2 RCTs [32] . We applied the 12-week stopping rule to patients who received SOC. Patients who achieve early virologic response (EVR) by week 12 completed the full 48-week treatment period and patients who did not achieve EVR stopped treatment after 12 weeks [43] . We assumed that 14 % of patients without cirrhosis will fail to achieve EVR [44] and a 15 % reduction in the probability to achieve EVR in patients with compensated cirrhosis.
Utility Data
In the absence of SA-specific utility data, two systematic reviews and one original study [27, 37, 38] were used as references for health state utility values used in our model. The utility values assigned in the model are presented in Table 1 . Serious adverse events associated with treatment were not considered; however, the model did take the disutility of treatment into account by considering lower utility values for those patients receiving treatment.
Cost Data
The model accounted for three types of HCV-related cost: drug regimen, treatment monitoring and health state (downstream liver disease complications). Costs of treatment cycles were expressed in South African rand (R) and US dollars (US$) at 2015 value. According to the South African third-party payer's perspective, only direct healthcare costs were considered-in particular, drug costs and the costs associated with disease management (diagnostic tests, routine blood tests, outpatient visits, hospitalisation, etc.) ( Tables 2, 3 ). Monitoring costs and recommended follow-up of patients were based on typical South African management of HCV and were confirmed by expert opinion (independent South African hepatologists). Costs of laboratory tests, radiological examination and consultations were based on the prices in the Referencing Price List (RPL), and were calculated according to specified monitoring resource use [45] . The latest RPL values (2009) were inflated using published annual medical inflation numbers from Statistics South Africa (STATS SA) and total monitoring costs over the treatment period were aggregated from calculated totals [46] . Drug costs included the costs of pegylated interferon, ribavirin, sofosbuvir and SOF/LDV, and drug regimen costs were based on unit drug costs, indicated drug dosing and therapy duration. Unit prices of pegylated interferon and ribavirin were taken from the Official Pharmaceutical Bluebook [47] . The medicine price used to populate the model was a composite of single exit price (SEP), 3 value-added tax (VAT) and the prescribed professional dispensing fee. A detailed description of the costs and calculations can be found in the Online Resource.
The FDA approved sofosbuvir in December 2013 and SOF/LDV in October 2014 for the treatment of HCV. In the USA, sofosbuvir and SOF/LDV are priced at US$84,000 (*R985,552) and US$94,500 (*R1,108,746) for 12 weeks, respectively [49] . In September 2014, Gilead signed an agreement with seven India-based generic pharmaceutical manufacturers to develop sofosbuvir and SOF/LDV for distribution in 91 developing countries [50] . Under the licensing agreement, the generic manufacturers have the right to develop and market generic sofosbuvir and SOF/LDV in certain countries, including SA [51] .
In 2015, generic manufacturers began selling sofosbuvir generics in India for about US$960 for a 12-week regimen [52] . In Pakistan and Brazil, the governments opted for negotiating prices exclusively with Gilead and entered into agreements with the manufacturer to distribute Sovaldi Ò at subsidised rates of approximately US$1500 and US$7000, respectively [53, 54] . In 2014, Gilead initiated a partnership with Egypt, agreeing to provide Sovaldi and Harvoni Ò to the country at a significantly reduced cost [55] . Sovaldi Ò is currently sold at a price of US$900 and Harvoni Ò at a price of US$1200 for a 12-week treatment in Egypt, the lowest available prices in the world. Although SA might not be able to get these drugs at a price similar to Egypt, Egypt has demonstrated that with effective leadership and government support, price reductions are achievable. Because SA is included in the list of countries for distribution of the generic versions of sofosbuvir and SOF/LDV, it will almost certainly be able to have access to these drugs at a lower price. At the time of this analysis, SOF/LDV generics and information on their pricing were not yet 
Model Analysis
Comparisons of health and economic outcomes were made across treatment regimens for the modelled cohort. The long-term health economic outcomes included discounted and undiscounted lifetime costs (in South African rand and US dollars), discounted and undiscounted LYGs, discounted and undiscounted quality-adjusted life-years (QALYs) and incremental lifetime cost per QALY gained (incremental cost-effectiveness ratios [ICERs]). The primary outcome was QALYs, calculated by applying utility values to LYGs. The incremental lifetime cost per QALY gained for sofosbuvir-based therapy was compared against the willingness-to-pay (WTP) threshold of R200,000 (*US$17,046) per QALY. 4 
Sensitivity Analysis
Deterministic and probabilistic sensitivity analyses were conducted. The one-way sensitivity analysis assessed the impact of individual changes to model inputs and assumptions on model results. Key parameters varied included SVR rates (±10 % to a maximum of 99 %), AFP a-fetoprotein, HCC hepatocellular carcinoma, R South African rand, RBV ribavirin, SOC standard of care, SOF sofosbuvir, SOF/LDV sofosbuvir-ledipasvir, SVR sustained virologic response a The 12-week stopping rule was applied to patients who failed to achieve early virologic response. Costs applied to patients who discontinued treatment after 12 weeks were calculated as 12 weeks' drug cots and two-thirds of monitoring costs associated with SOC, for both cirrhotic and non-cirrhotic patients b The total annual cost of decompensated cirrhosis is a weighted average between the average annual cost of ascites, variceal bleed and hepatic encephalopathy, calculated by multiplying the average annual cost for each sequelae by fixed proportions derived from the literature: ascites, 62 %; variceal haemorrhage, 28 %; and hepatic encephalopathy, 10 % c The cost for oesophageal varices is a weighted average between the average annual cost of bleeding (R362,309.00) and non-bleeding (R32,083.00) varices, assuming that, on average, varices have a 30 % chance of bleeding d Patients without cirrhosis who did not achieve SVR have a liver biopsy every 5 years after treatment failure, whereas patients with compensated cirrhosis have a liver biopsy every 3 years after treatment failure e For patients with cirrhosis who achieve SVR, the cost of HCC screening (using AFP and liver ultrasound) every 6-12 months was included transition probabilities (95 % confidence interval), costs for health states (±20 %) and utility values (range, minimum and maximum values taken from the literature). We conducted the probabilistic sensitivity analysis (PSA) by running 1000 simulations, varying cost (±10 %) and transition probabilities (±10 %) by gamma-distribution, and SVR rate (±10 %) and utility values (±20 %) by betadistribution. Table 4 presents the projected number of cases of advanced liver disease complications and the number of cases of SVR over a lifetime period for the modelled cohort in both treatment arms. Sofosbuvir-containing treatments for HCV-G5 patients improve health outcomes and reduce HCV-related morbidity and mortality compared with current SOC. Sofosbuvir-based regimens were associated with the lowest number of liver-related complications and mortality per 10,000 patients, yielding a 90 and 71 % reduction when compared with SOC for SOF/LDV and SOF-TT, respectively. Compared with SOF-TT, treating patients with SOF/LDV reduced liver-related complications and deaths by 68 %.
Results
SOF/LDV yielded the highest overall SVR rate (93.8 %) compared with the overall SVR rates of 88.5 % for SOF-TT and 52.3 % for SOC. In addition to a higher SVR rate, patients treated with SOF/LDV lived 0.15 and 0.64 years longer, and gained 0.25 and 1.9 more QALYs than those treated with SOF-TT and SOC, respectively. SOF/LDV was associated with the lowest discounted lifetime cost (R241,561 or *US$20,589), followed by SOF-TT (R263,132 or *US$22,472) ( Table 5 ). The total discounted lifetime cost of patients (Table 5 ) treated with SOC (R392,127 or *US$33,422) was almost 32 and 38 % higher than those of patients treated with SOF-TT and SOF/LDV, respectively. Results from the cost-effectiveness analysis (CEA) showed that SOF-TT was the optimal strategy in treating patients with HCV-G5. In the base-case analysis, SOF/LDV dominated (i.e. was less costly and more effective than) both SOF-TT and SOC. Even though SOF-TT was not the optimal strategy, it still dominated SOC.
Subgroup Analyses
In the first subgroup analysis, we evaluated the impact of the 12-week stopping rule on cost. In this analysis, the stopping rule was not considered in patients treated with SOC, and all patients who started treatment with SOC completed a 48-week course (overall SVR rate 55.3 %). In this scenario, the total lifetime cost of patients treated with SOC was approximately 7 % higher than when the stopping rule was applied; however, SOF/LDV was still the dominant strategy. In the second subgroup analysis, we considered treating patients with cirrhosis in the SOF/LDV arm with 24 weeks of SOF/LDV monotherapy instead of 12 weeks with SOF/ LDV ? ribavirin (SOF/LDV ? RBV). 5 In this scenario, SOF/LDV remained the preferred strategy, even though the total lifetime cost of SOF/LDV was more (R263,132 or US$22,427) than for SOF-TT, yielding an ICER of R7992 (US$681).
Sensitivity Analysis
Results from the deterministic sensitivity analysis (DSA) showed that SOF/LDV and SOF-TT continued to dominate SOC for all values of key parameters varied, and SOC was excluded as the least favourable option. Figure 2 presents results of the DSA for SOF/LDV compared with SOF-TT. It displays the 11 parameters that most heavily influenced the ICER. The main input drivers of the ICER were SVR rates of SOF/LDV and SOF-TT, and utility values in the CHC state during treatment with SOF-TT. One-way sensitivity analysis showed that the net monetary benefit of SOF/LDV decreased with a decrease in the SVR rates for SOF/LDV, increased SVR rates of SOF-TT and increased utility in the CHC state during treatment with SOF-TT. Threshold analysis showed that SOF/LDV continued to be cost effective at a WTP threshold of R200,000, even at the maximum and minimum values of the range set for each of these parameters. Only when SVR rates for SOF/ LDV were \0.834, and the cost of SOF-TT and SOF/LDV were \R63,730 (US$5432) or [R209,143 (US$17,826), respectively, did SOF-TT become the preferred strategy. Figure 3 (incremental cost-effectiveness scatterplot graph) and Fig. 4 (cost-effectiveness acceptability curve) show results from the PSA. We conducted a PSA on the ten parameters that most heavily influenced the ICER during the DSA, as well as on all treatment and monitoring costs to see how combined uncertainty affects the overall confidence in our base-case conclusions. According to the PSA, the probability of SOF/LDV being the optimal strategy was 83.5 % at the WTP threshold of R200,000 when key clinical and cost parameters were adjusted across wide but plausible ranges.
Discussion
This study comprises a health economic analysis of sofosbuvir-based treatments for the treatment of patients with HCV-G5. Our cost-effectiveness model demonstrates that in SA, the SOF/LDV combination yields the most favourable future health economic outcomes compared with the current SOC. Compared with SOC and SOF-TT, SOF/LDV was associated with the lowest incidence of liver disease complications and HCV-related deaths, due to increased efficacy in cirrhotic and non-cirrhotic patients. Findings from the base-case analysis relating to the lifetime incremental cost per QALY gained for patients infected with HCV-G5 indicate that SOF/LDV dominates SOF-TT and SOC, viz. SOF/LDV is less costly and more effective than both SOF-TT and SOC. Results from the subgroup analysis relating to the SOF/LDV arm showed that treating cirrhotic patients with 24 weeks' monotherapy is less cost effective than 12 weeks of SOF/LDV ? RBV, but still more cost effective than SOF-TT and SOC overall. Results from the sensitivity analysis indicates that SOF/LDV continued to be a cost-effective strategy even when key clinical and cost parameters were adjusted across wide, yet plausible, ranges.
Cost effectiveness has been demonstrated for sofosbuvircontaining regimens across all genotypes, even at the current US price [58] . Recently published CEAs have revealed that HCV treatment regimens including sofosbuvir are generally cost effective when compared with existing treatment regimens [58] [59] [60] [61] [62] [63] [64] . A study comparing SOF/LDV with interferon-based therapies found that SOF/LDV was cost effective in over 80 % of patients, depending on genotype and treatment experience [59] . Another study found that SOF/LDV decreased the number of advanced liver disease cases by 0-93 % compared with current regimens or no treatment in treatment-naïve patients and treatment-experienced patients, and with regard to lifetime incremental costs per QALY gained, SOF/LDV was either dominant or the most cost-effective treatment [60] . Data comparing sofosbuvir-based regimens with currently recommended treatments in a mixed cohort of mono-infected and co-infected CHC patients with genotypes 1-4 in France reported that sofosbuvir, at the early access programme price, is a costeffective strategy in chronic HCV infection treatments at a commonly accepted threshold of €40,000 (*US$46,000) [61] . Another CEA that compared sofosbuvir-based regimens and standard treatments in treatment-naïve patients with HVC-G1 reported that treatment with sofosbuvir is cost effective in HCV-G1 patients with CF2 fibrosis [62] . A study comparing sofosbuvir-, boceprevir-and telaprevir-based therapies reported that sofosbuvir-based regimens were cost effective compared with boceprevir, except in cirrhotic and IL-28B CC patients, and mostly cost effective compared with telaprevir [63] . US data concluded that sofosbuvir-based treatment regimens generally dominate telaprevir-or boceprevir-based regimens, and compared with peg-INF/ RBV had incremental costs per QALYs gained well below the US WTP threshold of US$50,000 [64] .
Overall, cost-effectiveness studies support sofosbuvirbased treatment as a cost-effective option for most HCV genotypes. When comparing QALYs gained, findings from our CEA support those from other recently published costeffectiveness studies [60, 61, 64, 65] ; however, our costeffectiveness model found a much lower incremental cost per QALY gained than the previous CEA. This is mainly because we modelled a discounted cost for sofosbuvir and SOF/LDV, whereas studies conducted in Europe [61, 65] and the USA [64] modelled the current respective prices for sofosbuvir and SOF/LDV (ranging between US$84,000 and €60,000) in their analyses. This highlights the fact that transferability of cost-effectiveness results between different countries is limited due, for example, to differences in epidemiology of the disease, clinical practice, consumer preferences and price levels. Hence, the cost effectiveness of sofosbuvir and SOF/LDV is dependent on its price and the cost-effectiveness threshold of the given country in which a CEA is performed.
Potential limitations of this model exist. First, it is largely populated with clinical trial data, which do not necessarily represent a real-world environment. Real-world SVR rates and patient adherence associated with the modelled treatment regimens may be substantially lower and the frequency of adverse effects may be higher than reported in clinical trial settings. Moreover, we obtained SVR rates for each treatment arm in our model from separate studies, as no head-to-head clinical trials including sofosbuvir and SOC were available at the time of this analysis. Also, as patients' demographic and clinical characteristics are different across clinical trials, SVR rates are influenced. Furthermore, our model only considers a treatment-naive cohort and does not demonstrate if there is a difference in the cost effectiveness of sofosbuvir-based therapy in treatment-experienced patients. We also assumed fibrosis progression in non-cirrhotic patients to be linear; however, studies have shown that fibrosis progression accelerates in the latter stages of the disease [66] . We compensated for accelerated fibrosis progression with increasing age by discriminating cohorts according to age. Our model also disregards the effect of risk factors such as increased alcohol consumption on fibrosis progression, since we did not model for co-morbidities or associated risk factors. This might also underestimate our all-cause mortality, as studies have indicated increased all-cause mortality in HCV populations due to increased co-morbidities [67] . In addition, we did not take HIV into account as a potential confounder of treatment efficacy. This might be important for SA, as an estimated 12.2 % of the South African population (6.4 million persons) are HIV positive [68] . Studies have also indicated a significantly higher prevalence of HCV among HIV-infected patients than in HIV-negative patients (13.4 vs. 1.73 %) [69] . Evidence on improved efficacy of sofosbuvir in HIV-infected cohorts over the current SOC notwithstanding [70, 71] , efficacy data of sofosbuvir in HIV-positive HCV-G5 patients are unavailable. However, HIV infection is an important confounding factor when considering the cost effectiveness of sofosbuvir-based therapy in the South African population. Other sofosbuvir combinations are currently being tested in ongoing trials, e.g. GS-9669 (non-structural protein [NS] 5B non-nucleoside inhibitor) [72] and GS-5816 (second-generation NS5A inhibitor) [73] , and further guideline adaptations may follow. These drugs remain unregistered and unavailable in SA; however, with recent findings on the efficacy of drugs such as sofosbuvir and SOF/LDV in HCV-G5, future research is warranted on the cost effectiveness of new HCV drugs in SA.
Conclusion
Outcomes from this analysis suggest that, at a price of R123,193 (US$10,500) for 12 weeks, the fixed-dose combination of sofosbuvir and ledipasvir might be cost effective for South African patients infected with HCV-G5. Considering the rapid progress in HCV therapies and the recent approval of all-oral, interferon-free regimens, it is essential to push for improved access to these drugs. The burden of hepatitis C in SA may not be substantial, but the principles learnt from our struggle with HIV should be applied in this instance-the issues are intrinsically the same and warrant no different a response. Conflict of interest Ilanca Fraser does not report competing interests. Johanita Burger does not report competing interests. Martie Lubbe does not report competing interests. George Dranitsaris does not report competing interests. As a potential competing interest, Mark Sonderup reports that he has consulted to Gilead Sciences Inc. in the past five years. As a potential competing interest, TS reports that, as an employer of HEXOR (Pty) Ltd., he has consulted to Gilead Sciences, Inc. in the past five years.
